Table 2.
Baseline clinical characteristics of patients in CALGB 80303 and 80203.
| CALGB 80303 | CALGB 80203 | ||
|---|---|---|---|
| Number of patients | 216 | 114 | |
| Sex | Male | 118 | 68 |
| Female | 98 | 46 | |
| Age (years) | Median (range) | 64 (35–84) | 63 (23–83) |
| Extent of disease | Metastatic | 183 | 110 |
| Locally Advanced | 33 | 3 | |
| Unknown | 0 | 1 | |
| Performance status | ECOG 0 or 1 | 195 | 114 |
| 2 | 21 |
Patients in the primary analysis population, i.e., having both genotype and circulating protein data, are summarized. Summaries are restricted to CALGB 80303 patients estimated to be genetically European and CALGB 80203 patients who self-reported as white and non-Hispanic. Patients with ECOG status 2 were excluded from registration to the CALGB 80203 clinical study per protocol.